CARA

Cara Therapeutics sits at a Underweight rating, with a composite score of 28 out of 100 and a conviction reading of 2 of 5. Weights are locked at 35 percent fundamentals, 25 percent regulatory, 25 percent market, and 15 percent editorial, and each pillar is broken out for direct review. The regulatory pillar contributes the largest share at 49, steadying the composite toward the lower edge of the band. Opposite that, fundamentals prints only 2, and is what keeps the rating anchored where it is.

The scoring inputs are concrete: reported revenue growth of -51.6 percent year over year, an operating margin of -412.4 percent, gross margin of -409.9 percent. Together they explain most of the pillar mix. Inputs are limited to primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, plus a density read from CIN newsroom coverage. The rating enables direct comparison across the 336 tickers in the CIN coverage universe on a consistent, deterministic basis, and refreshes on a scheduled cadence tied to the primary-source ingest cycle.

Watch the regulatory pillar, which drives 49 of the composite. Continued filing cadence at or above the trailing 90-day pace, matched with a clean enforcement record, would justify moving toward the upper band edge.